Showing 3021-3030 of 5621 results for "".
- Heidelberg Engineering Presents Various Scientific Innovations at ARVOhttps://modernod.com/news/heidelberg-engineering-presents-various-scientific-innovations-at-arvo/2480819/Heidelberg Engineering showcases its research capabilities at this year’s ARVO congress that takes place in Denver, Colorado, USA, from May 1–4. The team looks forward to reconnecting with the global research community after 2 years of solely virtual ARVO meetings, and to demonstratin
- Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission of Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-of-nyxol-for-reversal-of-mydriasis/2480812/Ocuphire Pharma announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). The results demonstrated that Nyxol’s efficacy and safety in pediatric subjects 3-11 ye
- Study Covering 2,000 Patients Over 10 Years Using ForeseeHome AMD Remote Monitoring Shows Better Outcomes for Patientshttps://modernod.com/news/study-covering-2000-patients-over-10-years-using-foreseehome-amd-remote-monitoring-shows-better-outcomes-for-patients/2480802/
- Ocular Therapeutix to Present Preclinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2480797/Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting being held May 1-4 in Denver, Colorado and May 11-12 virtually. “At this year’s annual meeting, we are thrilled to be presenting c
- 'Love Your Eyes' Confirmed as the Theme for World Sight Day 2022https://modernod.com/news/love-your-eyes-confirmed-as-the-theme-for-world-sight-day-2022/2480763/The International Agency for the Prevention of Blindness (IAPB) has confirmed it will continue the theme of #LoveYourEyes for World Sight Day 2022. World Sight Day 2021 saw over 3.5 million eye test pledges made by individuals, eye care professionals, hospitals, NGOs and businesses. Thi
- Mireca Signs Deal with Graybug Vision to Develop Treatments for Inherited Retinal Diseaseshttps://modernod.com/news/mireca-signs-deal-with-graybug-vision-to-develop-treatments-for-inherited-retinal-diseases/2480755/
- Researchers Identify How Multiple Genes Impact Vision Development and Result in Rare Sight Disorderhttps://modernod.com/news/researchers-identify-how-multiple-genes-impact-vision-development-and-result-in-rare-sight-disorder/2480744/
- Heru Featured in Scientific Program with Hands-On Demonstrations at the 2022 Vision Expo East Annual Meetinghttps://modernod.com/news/heru-featured-in-scientific-program-with-hands-on-demonstrations-at-the-2022-vision-expo-east-annual-meeting/2480739/Heru, a provider of vision diagnostics, announced that the company will be featuring two new testing moda
- Penn Researchers Develop Gene Therapy that Restores Dim-Light Vision in Dogshttps://modernod.com/news/penn-researchers-develop-gene-therapy-that-restores-dim-light-vision-in-dogs/2480723/In the journal Proceedings of the National Academy of Sciences, University of Pennsylvania researchers reported a major advance: a gene therapy that returns night vision to dogs born with congenital stationary night blindness
- Study Shows Eyenovia's Optejet Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutionshttps://modernod.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/Eyenovia announced positive results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from latanoprost+benzalkonium chloride (BAK) treatment administered via